Expert Interview
Exploring the Breakthroughs in Early Alzheimer's Disease: Discussing Leqembi with a Prescriber & Examining the TRAILBLAZER-ALZ 2 Phase 3 Study ahead of Early 2024 PDUFA Decision
Ticker(s): BIIB, LLY, ESALF, EII.XFRAInstitution: Washington University School of Medicine
- Medical Director of the Memory Diagnostic Center and Director of the Knight ADRC Clinical Trials Unit team conducting clinical therapeutic trials for people with Alzheimer disease and other dementias at WUSTL.
- Currently manages 300+ patients with memory disorder and roughly 200+ patients with Alzheimer disease.
- Research focuses on the diagnosis and treatment of neurodegenerative disorders, specifically dementing disorders; Principal Investigator for numerous clinical therapeutic trials.
The TRAILBLAZER-ALZ 2 study showed a 35% slowing in clinical decline with donanemab. Could you elaborate on the significance of this result in the context of early Alzheimer's disease treatment?
Added By: slingshot_insightsWith donanemab leading to 40% less decline in activities of daily living, how do you see this impacting the quality of life for patients with early Alzheimer's disease?
Added By: slingshot_insightsGiven that donanemab targets amyloid plaques, can you discuss the importance of this approach in Alzheimer's disease treatment and how it compares to other strategies?
Added By: slingshot_insightsThe study reports ARIA occurrences in the donanemab group. Could you explain what ARIA is and how it affects the overall safety profile of donanemab?
Added By: slingshot_insightsParticipants in the study were stratified by their level of brain protein tau. How does this biomarker influence the progression of Alzheimer's and the effectiveness of treatments like donanemab?
Added By: slingshot_insightsDonanemab showed a 39% lower risk of disease progression. What does this mean for the potential long-term outcomes for patients?
Added By: slingshot_insightsThe study included participants with varying levels of tau, indicating different stages of Alzheimer's. How did donanemab perform across these different stages?
Added By: slingshot_insightsWith Lilly approaching regulatory decision for donanemab, what are the next steps, and what should the medical community and patients expect in terms of availability and access to this treatment?
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
